Catapres-TTS-2 Transdermal and Daclizumab Subcutaneous

• Generic Name: clonidine
• Dosage Forms: patch, extended release
• Other Brand Names:

  Catapres-TTS-1, Catapres-TTS-2, Catapres-TTS-3, Catapres, Catapres-TTS, Duraclon, Kapvay

Clonidine transdermal is used alone or together with other medicines to treat high blood pressure (hypertension). High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. High blood pressure may also increase the risk for heart attacks. These problems may be less likely to occur if the blood pressure is controlled.

Clonidine belongs to the class of medicines called antihypertensives. It works in the brain to change some of the nerve impulses. As a result, the blood vessels relax and blood passes through them more easily, which lowers blood pressure. When the blood pressure is lowered, the amount of blood and oxygen going to the heart is increased.

This medicine will not cure your high blood pressure, but it does help control it. Therefore, you must continue to use it as directed if you expect to lower your blood pressure and keep it down. You might have to take high blood pressure medicine for the rest of your life.

This medicine is available only with your doctor's prescription.

• Generic Name: daclizumab
• Dosage Forms: n.a.
• Other Brand Names: Zinbryta, Zenapax

Daclizumab injection is used to treat the relapsing forms of multiple sclerosis (MS). Daclizumab will not cure MS, but it may slow some of the disabling effects and decrease the number of relapses of the disease. It should only be used when other medicines to treat MS did not work well.

Daclizumab was available only under a restricted distribution program called the Zinbryta® REMS (Risk Evaluation and Mitigation Strategy) Program.

Daclizumab was voluntarily withdrawn from the worldwide market on March 2, 2018 due to safety concerns.